Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCART19 in Adult R/R B-ALL (CALM)
NCT02746952Phase 1Completed
- Sponsor
- Servier
- Start
- Aug 2016
- Primary completion
- Jul 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of UCART19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Servier. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 12 months. Started Aug 2016; status: completed.
02
Drugs
UCART19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02746952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02746952.